此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer (PROSTA-PAP)

2022年10月24日 更新者:Assistance Publique - Hôpitaux de Paris

Non-invasive Isolation and Characterization of Prostate Tumor Cells for Prostate Cancer Diagnosis

The purpose of this study is to isolate and characterize tumor cells non-invasively from biological samples in patients with prostate cancer and demonstrate the ability to identify the presence and number of tumor cells before prostate biopsy.

研究概览

详细说明

Prostate cancer is one of the most frequently diagnosed cancers and a leading cause of cancer death in men worldwide. Existing methods of diagnosis and monitoring of prostate cancer are inadequate due to their invasiveness, inaccuracy, cost, access uneven, etc., making difficult the diagnosis and patient's follow up. New techniques and methods are necessary to improve diagnosis.

Biological liquids might represent an attractive target to isolate prostate tumour cells for these purposes. In recent years, several studies have been carried out with the aim of reducing and / or avoiding the limits of sensitivity and specificity of current methods of screening for prostate cancer and thus obtain new biomarkers for the diagnosis and / or non-invasive monitoring.

However, due to technical and technological difficulties few studies have been performed to investigate the non-invasive isolation and direct analysis of tumour cells. Our project is therefore an innovative project which aims to study a new approach for the early diagnosis of prostate cancer, with better sensitivity and specificity.

研究类型

观察性的

注册 (预期的)

200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Paris、法国、75014
        • 招聘中
        • Cochin Hospital
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

是的

有资格学习的性别

男性

取样方法

非概率样本

研究人群

Patients consulting the urology department of Cochin Hospital with an indication for prostate biopsy or as part of the monitoring of prostate cancer may be included.

描述

Inclusion Criteria:

  • Patients with a diagnosis of localized or metastatic prostate cancer.
  • No prior or other oncological treatment.
  • Patients undergoing prostate biopsy in the context of prostate cancer diagnosis.
  • Patients with an elevation of PSA (Prostate Specific Antigen), an abnormality on the rectal examination and / or an MRI signal motivating a prostate biopsy,
  • Patients informed and not opposed to participating in the research

Exclusion Criteria:

  • Patients not affiliated with French social security.
  • Patients unable to understand the protocol.
  • Patients diagnosed with another type of cancer within the past 5 years.
  • Patients prostatectomized and/or treated for prostate cancer.
  • Patients who wear a bladder catheter
  • Patients under guardianship or curatorship
  • Patients under AME

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Confirmed diagnosis group
Patients with a diagnosis of prostate cancer (metastatic or advanced) before prostatectomy.
临床资料
Results obtained by biopsy and MRI results.
Pre-diagnosis group
Patients undergoing prostate biopsy in the context of prostate cancer diagnosis: PSA increases, and / or abnormal digital rectal examination (DRE) and / or an MRI detected signal.
临床资料
Results obtained by biopsy and MRI results.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Presence and number of prostate tumour cells in biological samples
大体时间:One month after biopsy or until the histological diagnosis will be obtained
Cell enrichment will be carried out using the ISET® (Isolation by SizE of Tumor/Trophoblastic cells) technology. Identification will be performed by different spectroscopic and/or immune-molecular and/or cytological approaches
One month after biopsy or until the histological diagnosis will be obtained

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Patrizia PATERLINI-BRECHOT, MD, PhD、INSERM and Rarecells Diagnostics

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年3月19日

初级完成 (预期的)

2024年3月19日

研究完成 (预期的)

2024年3月19日

研究注册日期

首次提交

2021年1月7日

首先提交符合 QC 标准的

2021年1月8日

首次发布 (实际的)

2021年1月11日

研究记录更新

最后更新发布 (实际的)

2022年10月25日

上次提交的符合 QC 标准的更新

2022年10月24日

最后验证

2022年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

药物和器械信息、研究文件

研究美国 FDA 监管的药品

研究美国 FDA 监管的设备产品

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

临床资料的临床试验

3
订阅